Seagen Stock Forecast, Price & News

-4.14 (-2.77 %)
(As of 04/16/2021 04:00 PM ET)
Today's Range
Now: $145.50
50-Day Range
MA: $146.03
52-Week Range
Now: $145.50
Volume1.19 million shs
Average Volume1.16 million shs
Market Capitalization$26.38 billion
P/E Ratio57.28
Dividend YieldN/A
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; and Merck. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Seagen logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:SGEN
Year Founded1998



Sales & Book Value

Annual Sales$916.71 million
Book Value$10.95 per share


Net Income$-158,650,000.00


Market Cap$26.38 billion
Next Earnings Date4/29/2021 (Confirmed)


Seagen: The New Oncology Hope - Seeking Alpha
April 12, 2021 |
Seagen Inc. (NASDAQ:SGEN) Short Interest Down 18.5% in March
April 1, 2021 |
Credit Suisse Group Begins Coverage on Seagen (NASDAQ:SGEN)
March 30, 2021 |
See More Headlines


Overall MarketRank

1.70 out of 5 stars

Medical Sector

277th out of 2,025 stocks

Biological Products, Except Diagnostic Industry

33rd out of 177 stocks

Analyst Opinion: 4.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-4.14 (-2.77 %)
(As of 04/16/2021 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Seagen (NASDAQ:SGEN) Frequently Asked Questions

Is Seagen a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 1 sell rating, 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen
or view top-rated stocks.

What stocks does MarketBeat like better than Seagen?

Wall Street analysts have given Seagen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seagen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Seagen?

Seagen saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,670,000 shares, an increase of 43.9% from the March 15th total of 2,550,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 3.2 days.
View Seagen's Short Interest

When is Seagen's next earnings date?

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Seagen

How can I listen to Seagen's earnings call?

Seagen will be holding an earnings conference call on Thursday, April 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Seagen's earnings last quarter?

Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Thursday, February, 11th. The biotechnology company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.81 by $0.09. The biotechnology company had revenue of $601.29 million for the quarter, compared to analyst estimates of $583.58 million. Seagen had a trailing twelve-month return on equity of 20.46% and a net margin of 25.34%. During the same period in the previous year, the firm posted $0.14 earnings per share.
View Seagen's earnings history

How has Seagen's stock price been impacted by Coronavirus?

Seagen's stock was trading at $104.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SGEN stock has increased by 39.2% and is now trading at $145.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SGEN?

19 analysts have issued 1 year target prices for Seagen's stock. Their forecasts range from $129.00 to $254.00. On average, they anticipate Seagen's stock price to reach $185.36 in the next twelve months. This suggests a possible upside of 27.4% from the stock's current price.
View analysts' price targets for Seagen
or view top-rated stocks among Wall Street analysts.

Who are Seagen's key executives?

Seagen's management team includes the following people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 60, Pay $2.88M) (LinkedIn Profile)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 60, Pay $1.11M)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 53, Pay $1M) (LinkedIn Profile)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 64, Pay $1.74M) (LinkedIn Profile)
  • Dr. Vaughn B. Himes, Chief Technical Officer (Age 60) (LinkedIn Profile)
  • Peggy Pinkston, VP of Investor Relations
  • Ms. Nancy Whiting B.Sc., Pharm.D., Exec. VP of Corp. Strategy, Alliances & Communications (LinkedIn Profile)
  • Ms. Natasha A. Hernday, Exec. VP of Corp. Devel. (Age 49) (LinkedIn Profile)
  • Mr. Matt Skelton, VP of Marketing
  • Mr. Christopher P. Pawlowicz, Exec. VP of HR (LinkedIn Profile)

What is Clay B. Siegall's approval rating as Seagen's CEO?

107 employees have rated Seagen CEO Clay B. Siegall on Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Seagen's key competitors?

What other stocks do shareholders of Seagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

What is Seagen's stock symbol?

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seagen's major shareholders?

Seagen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Royal London Asset Management Ltd. (0.03%), State of Alaska Department of Revenue (0.02%), DnB Asset Management AS (0.02%), Louisiana State Employees Retirement System (0.01%), EFG Asset Management Americas Corp. (0.00%) and Addison Capital Co (0.00%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen

Which major investors are selling Seagen stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., State of Alaska Department of Revenue, and Addison Capital Co. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Marc E Lippman, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen
or view top insider-selling stocks.

Which major investors are buying Seagen stock?

SGEN stock was bought by a variety of institutional investors in the last quarter, including DnB Asset Management AS, EFG Asset Management Americas Corp., NuWave Investment Management LLC, Royal London Asset Management Ltd., Louisiana State Employees Retirement System, Redpoint Investment Management Pty Ltd, and Fulton Bank N.A..
View insider buying and selling activity for Seagen
or or view top insider-buying stocks.

How do I buy shares of Seagen?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seagen's stock price today?

One share of SGEN stock can currently be purchased for approximately $145.50.

How much money does Seagen make?

Seagen has a market capitalization of $26.38 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does Seagen have?

Seagen employs 2,092 workers across the globe.

When was Seagen founded?

Seagen was founded in 1998.

What is Seagen's official website?

The official website for Seagen is

Where are Seagen's headquarters?

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

How can I contact Seagen?

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.